Know Cancer

or
forgot password

AFP - L3% and DCP as Tumor Markers in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolisation (TACE)


N/A
18 Years
80 Years
Open (Enrolling)
Both
Hepatocellular Carcinoma

Thank you

Trial Information

AFP - L3% and DCP as Tumor Markers in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolisation (TACE)


Patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolisation
are enrolled in this clinical trial. The aim of this trial is to evaluate the usefulness of
the liver cancer markers AFP, AFP-L3% (subfraction of AFP) and des-y- carboxyprothrombin
(DCP) after TACE therapy. Some authors could have shown that AFP-L3% is rising in small
tumor nodules under 2 cm and so the markers which should decrease after TACE can give a hint
for the therapeutic response after the intervention. So the important aim of this trial is
to improve the early detection of tumor recurrence after TACE.

Furthermore the quality of life measured by the EORTC QLQ C30 before and after TACE is
evaluated.


Inclusion Criteria:



- age between 18 and 80

- diagnosis of HCC according the AASLD criteria

- TACE is planned

- resection is impossible

Exclusion Criteria:

- liver tumor of unknown origin

- other liver tumors

- TACE is impossible

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

comparison of liver cancer markers AFP, AFP-L3% and DCP before and after TACE

Outcome Description:

Liver cancer markers AFP, AFP-L3 and DCP are measured before TACE, 1 month and 3 months after TACE in order to evaluate the course of these markers after the intervention

Outcome Time Frame:

baseline, 1 month and 3 months

Safety Issue:

No

Principal Investigator

Hans Christian Spangenberg, Prof. Dr.

Investigator Role:

Principal Investigator

Investigator Affiliation:

University Medical Center Freiburg

Authority:

Germany: Ethics Commission

Study ID:

HCC2

NCT ID:

NCT01360255

Start Date:

May 2010

Completion Date:

December 2011

Related Keywords:

  • Hepatocellular Carcinoma
  • Hepatocellular Carcinoma
  • transarterial chemoembolisation
  • liver cancer markers: AFP, AFP-L3% and DCP
  • Carcinoma
  • Carcinoma, Hepatocellular

Name

Location